|
|
| (431 intermediate revisions by 28 users not shown) |
| Line 1: |
Line 1: |
| '''Do Not Delete'''
| | {{ACM}} {{SemRikken}} |
|
| |
|
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:GreenYellow"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| |'''a.''' LDL-C should be <100 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |'''b.''' If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |'''c.''' If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |'''d.''' If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''e.''' Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''f.''' If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C]])
| |
|
| |
|
| |}
| | ''SANDBOX'' |
| ----
| | [[File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png]] |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:Yellow"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| |'''a.''' Reduction of LDL-C to <70 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:A]])
| |
| |-
| |
| |'''b.''' If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''c.''' If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''d.''' Therapeutic options to reduce non HDL - C are [[Niacin]] (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''e.''' Therapeutic options to reduce non HDL - C are [[Fibrate]] therapy (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |}
| |
| | |
| ----
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:GreenYellow"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| |bgcolor="GreenYellow" |'''a.''' LDL-C should be <100 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |bgcolor="GreenYellow" |'''b.''' If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |bgcolor="GreenYellow" |'''c.''' If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |bgcolor="GreenYellow" |'''d.''' If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="GreenYellow" |'''e.''' Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="GreenYellow" |'''f.''' If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C]])
| |
| | |
| |}
| |
| ----
| |
| | |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:Yellow"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| |bgcolor="Yellow" |'''a.''' Reduction of LDL-C to <70 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:A]])
| |
| |-
| |
| |bgcolor="Yellow" |'''b.''' If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="Yellow" |'''c.''' If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="Yellow" |'''d.''' Therapeutic options to reduce non HDL - C are [[Niacin]] (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="Yellow" |'''e.''' Therapeutic options to reduce non HDL - C are [[Fibrate]] therapy (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |}
| |
| | |
| ----
| |
| {|class="wikitable"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:Maroon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
| |
| |-
| |
| |'''1.''' Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
| |
| |-
| |
| |'''2.''' Ongoing clinical screening is not indicated in genotype-negative relatives in families with [[HOCM]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
| |
| |}
| |
| | |
| ----
| |
| {|class="wikitable"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:Red"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
| |
| |-
| |
| |'''1.''' Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
| |
| |-
| |
| |'''2.''' Ongoing clinical screening is not indicated in genotype-negative relatives in families with [[HOCM]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
| |
| |}
| |
_9.33.11_p.m..png)